ACE — Ascelia Pharma AB Cashflow Statement
0.000.00%
- SEK274.08m
- SEK221.85m
Annual cashflow statement for Ascelia Pharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -93.4 | -138 | -147 | -111 | -67.8 |
| Non-Cash Items | 8.74 | 6.96 | 2.72 | 3.6 | 4.39 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.842 | 14.4 | 19 | -19.5 | 0.533 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -85.5 | -117 | -125 | -127 | -62.8 |
| Capital Expenditures | -0.397 | -0.038 | -0.065 | 0 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 76.4 | 0 | — | 0.047 | 0 |
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Cash from Investing Activities | 76 | -0.038 | -0.065 | 0.047 | 0 |
| Financing Cash Flow Items | -5.29 | -13.3 | -0.084 | -0.03 | -15.2 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 92.7 | 185 | -1.1 | -0.936 | 115 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 76.2 | 76.9 | -112 | -128 | 53.4 |